Last reviewed · How we verify
131-I-TM-601
131-I-TM-601 is a targeted alpha-particle therapy that selectively targets and destroys cancer cells.
131-I-TM-601 is a targeted alpha-particle therapy that selectively targets and destroys cancer cells. Used for Relapsed or refractory multiple myeloma.
At a glance
| Generic name | 131-I-TM-601 |
|---|---|
| Also known as | chlorotoxin |
| Sponsor | TransMolecular |
| Drug class | Targeted alpha-particle therapy |
| Target | CD47 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
It works by emitting alpha particles that damage the DNA of cancer cells, leading to cell death. This approach allows for a more targeted and less toxic treatment compared to traditional chemotherapy.
Approved indications
- Relapsed or refractory multiple myeloma
Common side effects
- Fatigue
- Nausea
- Vomiting
Key clinical trials
- 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma (PHASE2)
- 131-I-TM-601 Study in Adults With Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 131-I-TM-601 CI brief — competitive landscape report
- 131-I-TM-601 updates RSS · CI watch RSS
- TransMolecular portfolio CI